{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:59Z","timestamp":1793121539254,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["004-2018"],"award-info":[{"award-number":["004-2018"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p\/19q-codeleted, diagnosed\u2005\u2265\u20055\u2005years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor location; treatments delivered; time since treatment; current medication) were explored with regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 237 patients M\u2005=\u20059.9\u2005years postdiagnosis (SD\u2005=\u20054.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in &amp;gt;40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (posthoc analyses for cumulative radiotherapy dose: not significant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT04708548<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf172","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:20:40Z","timestamp":1753172440000},"page":"2959-2974","source":"Crossref","is-referenced-by-count":10,"title":["Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0409-7949","authenticated-orcid":false,"given":"Florien W","family":"Boele","sequence":"first","affiliation":[{"name":"Leeds Institute of Medical Research at St James\u2019s, St James\u2019s University Hospital, University of Leeds , Leeds"},{"name":"Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9 M","family":"Frances","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research at St James\u2019s, St James\u2019s University Hospital, University of Leeds , Leeds"},{"name":"Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Darlix","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier , Montpellier"},{"name":"Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8150-5785","authenticated-orcid":false,"given":"Francois","family":"Ducray","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital Neurologique, Neuro-oncology Department; Cancer Research Center of Lyon, Claude Bernard University , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Cartalat","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital Neurologique, Neuro-oncology Department , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-0791","authenticated-orcid":false,"given":"Estelle","family":"Guerdoux","sequence":"additional","affiliation":[{"name":"Department of Palliative and Supportive Care, Montpellier Cancer Institute, Univ Montpellier , Montpellier ,","place":["France"]},{"name":"Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Tabouret","sequence":"additional","affiliation":[{"name":"Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team, APHM, CHU Timone, Service de Neurooncologie, R\u00e9seau Pr\u00e9clinique et Translationnel de Recherche en Neuro-oncologie Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Burger","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2384-9248","authenticated-orcid":false,"given":"Isabelle","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Physiology, University of Gothenburg ,","place":["Sweden"]},{"name":"Department of Neurology, Sahlgrenska University Hospital ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Malmstrom","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Palliative Medicine and Division of Cell and Neurobiology, Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Vauleon","sequence":"additional","affiliation":[{"name":"Centre Eug\u00e8ne Marquis, Medical Oncology, INSERM U1242, University of Rennes , Rennes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-8975","authenticated-orcid":false,"given":"Tomas","family":"Kazda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University; Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-3720","authenticated-orcid":false,"given":"Mirjam","family":"Renovanz","sequence":"additional","affiliation":[{"name":"Tubingen University Hospital , Tubingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-4594","authenticated-orcid":false,"given":"Jan-Michael","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Welsh","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanghera","sequence":"additional","affiliation":[{"name":"Cancer Centre, University Hospitals Birmingham, Edgbaston , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dehais","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, AP-HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, DMU Neurosciences, Service de Neuro-oncologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi , Florence ,","place":["Italy"]},{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cM. Serio,\u201d University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McBain","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, The Christie NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaveta","family":"Mehta","sequence":"additional","affiliation":[{"name":"The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington , Wirral ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lord","sequence":"additional","affiliation":[{"name":"Tayside NHS Trust , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Jena","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Foweraker","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Foundation Trust , Nottingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-7434","authenticated-orcid":false,"given":"Keyoumars","family":"Ashkan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, King\u2019s College Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Pellegrin Hospital, Bordeaux University Hospital Center , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bourg","sequence":"additional","affiliation":[{"name":"Department of Neurology, C\u00f4te d\u2019Azur University , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, Center for Neurology, University Hospital Bonn , Bonn,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-6905","authenticated-orcid":false,"given":"Aaron","family":"Lawson McLean","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jena University Hospital - Friedrich Schiller University Jena , Jena ,","place":["Germany"]},{"name":"Comprehensive Cancer Center Central Germany , Jena Campus, Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-2895","authenticated-orcid":false,"given":"Caroline","family":"Hertler","sequence":"additional","affiliation":[{"name":"Competence Center Palliative Care, Department of Radiation Oncology, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Haldbo-Classen","sequence":"additional","affiliation":[{"name":"The Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke H","family":"Dahlrot","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital ; Department of Clinical Research, University of Southern Denmark , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Noel","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Institut de Canc\u00e9rologie de Strasbourg-Europe (ICANS) , Strasbourg ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Durando","sequence":"additional","affiliation":[{"name":"INSERM U1240 Imagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques (IMoST), Universit\u00e9 Clermont Auvergne; 2 Centre d\u2019Investigation Clinique UMR501; D\u00e9partement de Recherche Clinique, D\u00e9l\u00e9gation Recherche Clinique et Innovation, Centre Jean PERRIN; Service d\u2019oncologie m\u00e9dicale, Centre Jean PERRIN , Clermont-Ferrand ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Hrab","sequence":"additional","affiliation":[{"name":"Centre Francois Baclesse , Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Razis","sequence":"additional","affiliation":[{"name":"3rd Oncology Department, Hygeia Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Muhic","sequence":"additional","affiliation":[{"name":"Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-7911","authenticated-orcid":false,"given":"Martin","family":"Klein","sequence":"additional","affiliation":[{"name":"Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Psychology , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"2026021610073298600_CIT0001","first-page":"1231","article-title":"The 2021 WHO classification of tumors of the central","volume-title":"Neuro-Oncology","author":"Louis","year":"2021"},{"issue":"2","key":"2026021610073298600_CIT0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 classification of gliomas","volume":"44","author":"Wesseling","year":"2018","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"11","key":"2026021610073298600_CIT0003","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021610073298600_CIT0004","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.lanepe.2024.101078","article-title":"Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort study","volume":"46","author":"Ng","year":"2024","journal-title":"The Lancet Regional Health-Europe"},{"issue":"23","key":"2026021610073298600_CIT0005","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"Lassman","year":"2022","journal-title":"J Clin Oncol."},{"issue":"10","key":"2026021610073298600_CIT0006","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/neuonc\/noae107","article-title":"The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: how should they inform treatment decisions in the era of IDH inhibitors","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro-Oncology."},{"issue":"14","key":"2026021610073298600_CIT0007","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"issue":"3","key":"2026021610073298600_CIT0008","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"key":"2026021610073298600_CIT0009","volume-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","author":"Mohile","year":"2022"},{"issue":"11","key":"2026021610073298600_CIT0010","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"2026021610073298600_CIT0011","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1-or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."},{"key":"2026021610073298600_CIT0012","first-page":"5113","volume-title":"A randomized, double-blind, phase 3 study of vorasidenib versus placebo in patients with mutant IDH1\/2 diffuse glioma (INDIGO): analysis of health-related quality of life, neurocognition and seizures (PL5. 003)","author":"Peters","year":"2024"},{"key":"2026021610073298600_CIT0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/B978-0-12-813158-9.00024-4","article-title":"Proton beam therapy for oligodendroglioma","volume-title":"Oligodendroglioma","author":"Williams","year":"2019"},{"issue":"1","key":"2026021610073298600_CIT0014","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1186\/s12885-022-09720-z","article-title":"Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p\/19q\u2013IMPROVE CODEL: the NOA-18 trial","volume":"22","author":"Wick","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"2026021610073298600_CIT0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11136-022-03207-x","article-title":"Health-related quality of life in adults with low-grade gliomas: a systematic review","volume":"32","author":"Rimmer","year":"2023","journal-title":"Qual Life Res"},{"issue":"1","key":"2026021610073298600_CIT0016","first-page":"3","article-title":"Long-term impact of adult WHO grade II or III gliomas on health-related quality of life: a systematic review","volume":"9","author":"Frances","year":"2022","journal-title":"Neurooncol. Pract."},{"issue":"13","key":"2026021610073298600_CIT0017","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2003.04.172","article-title":"Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination","volume":"21","author":"Brown","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026021610073298600_CIT0018","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.56.10.1285","article-title":"Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients","volume":"56","author":"Surma-aho","year":"2001","journal-title":"Neurology."},{"issue":"9343","key":"2026021610073298600_CIT0019","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(02)11398-5","article-title":"Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study","volume":"360","author":"Klein","year":"2002","journal-title":"Lancet."},{"issue":"4","key":"2026021610073298600_CIT0020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ijrobp.2005.04.016","article-title":"Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study","volume":"63","author":"Laack","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2026021610073298600_CIT0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410360111","article-title":"Cognitive functions and quality of life in patients with low-grade gliomas: The impact of radiotherapy","volume":"36","author":"Taphoorn","year":"1994","journal-title":"Ann Neurol."},{"issue":"9","key":"2026021610073298600_CIT0022","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"The Lancet Neurol"},{"issue":"8","key":"2026021610073298600_CIT0023","first-page":"CD013047","article-title":"Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma","author":"Lawrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021610073298600_CIT0024","doi-asserted-by":"crossref","first-page":"943600","DOI":"10.3389\/fonc.2022.943600","article-title":"Influences on cognitive outcomes in adult patients with gliomas: a systematic review","volume":"12","author":"Kirkman","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"2026021610073298600_CIT0025","first-page":"vdae084","article-title":"Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study","volume":"6","author":"Darlix","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"2026021610073298600_CIT0026","volume-title":"Living with and beyond cancer","author":"JLA Priority Setting Partnerships"},{"issue":"suppl 8","key":"2026021610073298600_CIT0027","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/neuonc\/nov283.01","article-title":"OP01THE UK top 10 clinical research priorities in neuro-oncology","volume":"17","author":"Grant","year":"2015","journal-title":"Neuro-Oncology."},{"issue":"1","key":"2026021610073298600_CIT0028","first-page":"10","article-title":"Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG","volume":"5","author":"Kurian","year":"2017","journal-title":"Neurooncol Pract."},{"issue":"6","key":"2026021610073298600_CIT0029","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2026021610073298600_CIT0030","first-page":"335","article-title":"Depression and anxiety in glioma patients","volume":"10","author":"van der Meer","year":"2023","journal-title":"Neurooncol Pract."},{"issue":"1","key":"2026021610073298600_CIT0031","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/cns.13.65","article-title":"Symptom management and quality of life in glioma patients","volume":"3","author":"Boele","year":"2014","journal-title":"CNS Oncol"},{"issue":"5","key":"2026021610073298600_CIT0032","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"2026021610073298600_CIT0033","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Euro J Cancer"},{"key":"2026021610073298600_CIT0034","volume-title":"Measuring functioning and well-being: the medical outcomes study approach","author":"Stewart","year":"1992"},{"issue":"3","key":"2026021610073298600_CIT0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1076\/clin.13.3.348.1749","article-title":"Construct and concurrent validity of the Hopkins Verbal Learning Test\u2013revised","volume":"13","author":"Shapiro","year":"1999","journal-title":"Clin Neuropsychol."},{"issue":"1","key":"2026021610073298600_CIT0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","article-title":"Hopkins verbal learning test\u2013revised: normative data and analysis of inter-form and test-retest reliability","volume":"12","author":"Benedict","year":"1998","journal-title":"Clin Neuropsychol."},{"issue":"5","key":"2026021610073298600_CIT0037","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/nprot.2006.390","article-title":"Administration and interpretation of the Trail Making Test","volume":"1","author":"Bowie","year":"2006","journal-title":"Nat Protocols."},{"issue":"4","key":"2026021610073298600_CIT0038","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF01997792","article-title":"Trail making test: normative values from 287 normal adult controls","volume":"17","author":"Giovagnoli","year":"1996","journal-title":"Ital J Neurol Sci."},{"issue":"4","key":"2026021610073298600_CIT0039","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/arclin\/11.4.329","article-title":"Benton controlled oral word association test: reliability and updated norms","volume":"11","author":"Ruff","year":"1996","journal-title":"Arch Clin Neuropsychol."},{"issue":"2","key":"2026021610073298600_CIT0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","article-title":"Trail Making Test A and B: normative data stratified by age and education","volume":"19","author":"Tombaugh","year":"2004","journal-title":"Arch Clin Neuropsychol"},{"key":"2026021610073298600_CIT0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research","volume":"118","author":"Giesinger","year":"2020","journal-title":"J Clin Epidemiol."},{"key":"2026021610073298600_CIT0042","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer."},{"issue":"3","key":"2026021610073298600_CIT0043","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1017\/S1355617723000607","article-title":"Detecting cognitive decline in high-functioning older adults: The relationship between subjective cognitive concerns, frequency of high neuropsychological test scores, and the frontoparietal control network","volume":"30","author":"Karr","year":"2024","journal-title":"J Int Neuropsychol Soc"},{"key":"2026021610073298600_CIT0044","first-page":"1","article-title":"A tool for false positive rate estimation in cognitive impairment research: Handling correlated tests, small samples, and composite criteria","volume":"1","author":"Agelink van Rentergem","year":"2025","journal-title":"Clin Neuropsychol."},{"issue":"8","key":"2026021610073298600_CIT0045","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jocn.2013.11.027","article-title":"Surgical strategies in low-grade gliomas and implications for long-term quality of life","volume":"21","author":"Jakola","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"9","key":"2026021610073298600_CIT0046","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2014.56.9079","article-title":"Health-related quality of life in stable, long-term survivors of low-grade glioma","volume":"33","author":"Boele","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026021610073298600_CIT0047","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/neuonc\/noac185","article-title":"Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades","volume":"25","author":"Boele","year":"2023","journal-title":"Neuro-Oncology."},{"key":"2026021610073298600_CIT0048","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12885-021-07939-w","article-title":"Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study","volume":"21(1)","author":"Ryd\u00e9n","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"2026021610073298600_CIT0049","first-page":"11","article-title":"Cognitive impairment after cytotoxic chemotherapy","volume":"7","author":"Huehnchen","year":"2020","journal-title":"Neurooncol Pract."},{"issue":"5","key":"2026021610073298600_CIT0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1037\/neu0000064","article-title":"A meta-analysis of cognitive impairment following adult cancer chemotherapy","volume":"28","author":"Lindner","year":"2014","journal-title":"Neuropsychology."},{"issue":"3","key":"2026021610073298600_CIT0051","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11910-012-0264-9","article-title":"Chemotherapy-related cognitive dysfunction","volume":"12","author":"Wefel","year":"2012","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"3","key":"2026021610073298600_CIT0052","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ctrv.2012.11.001","article-title":"A meta-analysis of the effects of chemotherapy on cognition in patients with cancer","volume":"39","author":"Hodgson","year":"2013","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"2026021610073298600_CIT0053","first-page":"117","article-title":"Cognitive impact of lower-grade gliomas and strategies for rehabilitation","volume":"8","author":"Weyer-Jamora","year":"2021","journal-title":"Neurooncol Pract."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf172\/63816371\/noaf172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/11\/2959\/63816371\/noaf172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/11\/2959\/63816371\/noaf172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:07:47Z","timestamp":1771254467000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/11\/2959\/8210167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,19]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf172","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,19]]}}}